Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1261-1269

  Nie, Fang ^a   Yu, Xiao Ling ^a   Wang, Xiao Ge ^a   Tang, Yu Fu ^a   Wang, Ling Ling ^a   Ma, Lie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; CacyBP; COX 2; Invasion; Prognosis; Proliferation

Indexed keywords

CALCYCLIN BINDING PROTEIN; CYCLOOXYGENASE 2; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 77957859191     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000777     Document Type: Article

References (22)

1. Debatin K: Activation of apoptosis pathways by anticancer treatment. Toxicol Lett 112-113: 41-48, 2000.
2. Shao ZM, Li J, Wu J, Han QX, Shen ZZ, Fontana JA and Barsky SH: Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat 53: 263-269, 1999. (Pubitemid 29209895)
3. Filipek A and Wojda U: p30, a novel protein target of mouse calcyclin (S100A6). Biochem J 320: 585-587, 1996. (Pubitemid 126731812)
4. Filipek A and Kuznicki J: Molecular cloning and expression of a mouse brain cDNA encoding a novel protein target of calcyclin. J Neurochem 70: 1793-1798, 1998. (Pubitemid 28207800)
5. Filipek A, Jastrzebska B, Nowotny M and Kuznicki J: CacyBP/ SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J Biol Chem 277: 28848-28852, 2002.
6. Zhai H, Shi Y, Jin H, Li Y, Chen X, Wang J, Ding L, Wang X and Fan D: Expression of Calcyclin-binding protein/siah-1 interacting protein in normal and malignant human tissues: an immunohistochemical survey. J Histochem Cytochem 56: 765-772, 2008. (Pubitemid 351991089)
7. Ning X, Sun S, Hong L, Liang J, Liu L, Han S, Liu Z, Shi Y, Li Y, Gong W, Zhang S, Chen Y, Guo X, Cheng Y, Wu K and Fan D: Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res 5: 1254-1262, 2007. (Pubitemid 46903951)
8. Yang YJ, Liu WM, Zhou JX, Cao YJ, Li J, Peng S, Wang L, Yuan JG and Duan EK: Expression and hormonal regulation of calcyclin-binding protein (CacyBP) in the mouse uterus during early pregnancy. Life Sci 78: 753-760, 2006. (Pubitemid 41821133)
9. Sun S, Ning X, Liu J, Liu L, Chen Y, Han S, Zhang Y, Liang J, Wu K and Fan D: Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma. Biochem Biophys Res Commun 356: 864-871, 2007. (Pubitemid 46529373)
10. Chen X, Han G, Zhai H, Zhang F, Wang J, Li X, Huang S, Wang X and Fan D: Expression and clinical significance of CacyBP/SIP in pancreatic cancer. Pancreatology 8: 470-477, 2008.
11. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002.
12. Matsuzawa SI and Reed JC: Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7: 915-926, 2001.
13. Fuchs SY, Ougolkov AV, Spiegelman VS and Minamoto T: Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle 4: 1522-1539, 2005.
14. Peifer M and Polakis P: Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 287: 1606-1609, 2000.
15. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K and Harris CC: Regulation of cyclooxy-genase- 2 expression by the wnt and ras pathways. Cancer Res 63: 728-734, 2003.
16. Wang H, Wen S, Bunnett NW, Leduc R, Hollenberg MD and Macnaughton WK: Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein. J Biol Chem 283: 809-815, 2008.
17. Krysan K, Reckamp KL, Sharma S and Dubinett SM: The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 6: 209-220, 2006.
18. Chow LW, Loo WT and Toi M: Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother 59: S281-S284, 2005. (Pubitemid 43307921)
19. Amir M and Agarwal HK: Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 60: 563-570, 2005. (Pubitemid 41153417)
20. Brown JR and Dubois RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855, 2005. (Pubitemid 46179475)
21. Blanke C: Role of COX-2 inhibitors in cancer therapy. Cancer Invest 22: 271-282, 2004. (Pubitemid 38725182)
22. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282: 1254-1277, 1999.